What is Ipamorelin researched for?

Ipamorelin is described as a synthetic pentapeptide growth hormone secretagogue related to GHRP-1. The supplied source frames it as a research compound that can stimulate endogenous GH release, with human development focused mainly on postoperative ileus and gastrointestinal motility rather than wellness outcomes.

How does Ipamorelin work?

The source describes ipamorelin as acting at the ghrelin or growth hormone secretagogue receptor, GHS-R1a, on anterior pituitary somatotroph cells. That receptor activity is reported to promote pulsatile release of stored growth hormone through intracellular signaling involving phospholipase C, IP3, and calcium.

Is Ipamorelin FDA approved?

No. The source lists ipamorelin as not FDA approved and describes its clinical status as investigational, with Phase II trials discontinued. It also notes FDA Category 2 status with a pending reclassification process that had not formally changed the current category in the source.

What side effects are reported for Ipamorelin?

The source lists injection-site reactions, headache, nausea, increased appetite, water retention, and temporary joint stiffness. It also states that ipamorelin was generally well tolerated in the cited context and did not significantly increase cortisol or prolactin, while noting active malignancy as a contraindication.

What dose information is listed for Ipamorelin?

The source reports a community pattern of 200-300 mcg two to three times daily, with a broader per-dose range of 100-500 mcg. It also includes a research-labelled entry of 100-300 mcg per injection by subcutaneous administration. These are evidence-capture fields, not medical dosing instructions.

Hormon wzrostu Badania kliniczne - trwają badania u ludzi

Ipamorelin

Znany też jako: IPAM, NNC 26-0161

W skrócie

Zbiór danych PeptiGuide · przegląd sie 2026

Czym jest

Selective synthetic GH secretagogue studied for pituitary growth hormone release.

Status

Badania kliniczne

Poziom dowodów: badania z udziałem ludzi

Typowa dawka

200–300mcg

Subcutaneous injection

Badany pod kątem

Anti-aging, muscle building, sleep quality, recovery

Postęp badań

PrePrzedkliniczne
IFaza I
IIFaza II
IIIFaza III
IVFaza IV
FDAZatwierdzone przez FDA

Faza II - Wczesne dane u ludzi z istotnymi ograniczeniami

Użyj narzędzi

Prostym językiem

Synthetic pentapeptide growth hormone secretagogue associated with GHRP-1 and developed by Novo Nordisk.
Investigational compound; the source says Phase II development was discontinued and it is not FDA approved.
Human study context in the source centers on postoperative ileus and gut motility, while wellness uses are described as unproven extrapolations.
Source-reported community dosing is 200-300 mcg two to three times daily by subcutaneous injection.
Listed research-interest areas include anti-aging, muscle building, sleep quality, and recovery.

Jak prawdopodobnie działa

Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response.

Co pokazują badania

Na jakim etapie są badania

The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes.

Co pokazują

✓ Badania z udziałem ludzi

Wczesne dane u ludzi z istotnymi ograniczeniami

△ Ograniczenia

Protokoły badawcze opisują badania i nie są rekomendacjami dawkowania.

Podsumowanie: Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source. Not FDA Approved

Typowe dawkowanie

SpołecznośćZbiór danych społeczności

200–300 mcg

2-3x daily

100 mcgpełny obserwowany zakres500 mcg

Community-reported pattern only; the source also notes fasted timing, common use in the morning, after workouts, or before bed, and frequent pairing with CJC-1295.

Dawkowanie badawcze

Protokoły badawczeTrwają badania u ludzi - protokoły są specyficzne dla badań

Dawki obserwowane w badaniach

100-300 mcg per injection

Clinical Trial Data - Investigational - Phase II trials completed

Protokoły badawcze opisują badania i nie są rekomendacjami dawkowania.

Czas trwania: 8-12 weeks typical
Podanie: Subcutaneous injection

Timing i podanie

Najlepsza pora

Before bed or morning, fasted

2-3 times daily, with main dose before bed

Zalecenia żywieniowe

Fasted timing reported

Dlaczego taki timing?

The source links fasted use to a stronger GH-release response because food, especially carbohydrate or fat intake, may dampen that response. Bedtime timing is described as an attempt to coincide with sleep-related GH pulse patterns.

Możliwe skutki uboczne

Nie każdy ich doświadcza. Indywidualne reakcje zależą od dawki, czasu trwania i czynników osobistych.

Generally well tolerated
Injection-site reactions
Headache
Nausea
Increased appetite
Water retention
Temporary joint stiffness
No significant cortisol or prolactin elevation reported
Contraindicated with active malignancy

Nie każdy doświadcza skutków ubocznych, a nasilenie może zależeć od kontekstu, czystości, drogi podania i indywidualnych czynników zdrowotnych.

Źródła

PubMed ClinicalTrials.gov FDA.gov

Najczęstsze pytania

Sekwencja

H-Aib-His-D-2-Nal-D-Phe-Lys-NH2

Jeden otwarty zbiór danych

Każdy fakt na tej stronie - dawki, skutki uboczne, referencje - pochodzi z tego samego zbioru danych PeptiGuide, który zasila Tracker, Porównywarkę i Lab.

Przeglądaj zbiór danych

Zapisz na mojej liście Aktualizacje o Ipamorelin

Materiał edukacyjny, nie porada medyczna. Porozmawiaj z lekarzem, zanim podejmiesz działania.

Dyskusja społeczności

Komentarze są moderowane przed publikacją. Trzymajmy się dowodów.

Ipamorelin

Prostym językiemProstym językiem

Jak prawdopodobnie działaJak prawdopodobnie działa

Co pokazują badaniaCo pokazują badania

Typowe dawkowanie

Dawkowanie badawcze

Timing i podanieTiming i podanie

Możliwe skutki uboczneMożliwe skutki uboczne

ŹródłaŹródła

Najczęstsze pytaniaNajczęstsze pytania